ESH-iCMLf 16th International Conference Highlights in Chronic Myelogenous Leukemia

The Role of Monitoring in Patients Who Are Not Responding Adequately to Tyrosine Kinase Inhibitor Therapy
Timothy P. Hughes, MD

Begin

What Has Just Happened to the Safety of TKIs?
Michael J. Mauro, MD

Begin

The Impact of Ponatinib Dose Intensity on Selected Adverse Events
Michael J. Mauro, MD

Begin

Alternative Therapies in CML: What Can We Target When BCR-ABL Is Not Sufficient?
Danilo Perrotti, MD, PhD

Begin